Nura Bio is developing neuroprotective therapies that target axon degeneration and neuroimmune regulation to preserve neuronal integrity in patients with neurological diseases. By addressing the underlying mechanisms of these disorders, the company aims to halt disease progression and provide hope for effective treatments.
Funding
$141M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
TCFounders
Product
Problem
Neurological diseases often involve axon degeneration and dysregulation of the neuroimmune system, leading to a decline in neuronal integrity. Current treatments do not adequately address these underlying mechanisms, resulting in limited effectiveness in halting disease progression.
Solution
Nura Bio is developing a portfolio of neuroprotective therapies designed to preserve neuronal integrity by targeting the fundamental pathways of axon degeneration and neuroimmune regulation. The company's approach aims to directly address the underlying mechanisms of neurological disorders, offering the potential to halt or slow disease progression. By focusing on these core pathways, Nura Bio seeks to create more effective treatments that can significantly improve outcomes for patients with a range of neurological conditions. Their research and development efforts are geared towards identifying and developing novel therapeutics that can protect neurons from damage and promote their long-term survival.
Target Audience
The primary target audience includes patients suffering from neurological diseases and the healthcare professionals who treat them.
Features
- Focus on therapies targeting axon degeneration
- Modulation of neuroimmune response to protect neurons
- Development of novel therapeutics to preserve neuronal integrity